The U.S. Food and Drug Administration has approved higher doses of oral semaglutide, marketed as Rybelsus, for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The approval covers 25 mg and 50 mg tablets, a significant step up from the 14 mg dose previously available only for type 2 diabetes management.
Novo Nordisk, the drugmaker behind both Rybelsus and the injectable Wegovy, submitted the supplemental new drug application in August 2025 based on data from its OASIS clinical trial program. The FDA's decision marks the first time an oral GLP-1 receptor agonist has received a weight management indication.
What the Clinical Data Shows
The OASIS 1 trial enrolled 667 adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition such as hypertension, dyslipidemia, or obstructive sleep apnea. Participants who received the 50 mg oral semaglutide dose lost an average of 15.1% of their body weight over 68 weeks, compared to 2.4% in the placebo group [1].
Those numbers put oral semaglutide in a competitive range with injectable options. For comparison, the STEP 1 trial for injectable semaglutide (Wegovy) showed average weight loss of 14.9% over the same time frame [2]. The oral formulation is not identical in effect, but the gap is narrower than many clinicians expected.
Dr. Robert Kushner, a professor of medicine at Northwestern University's Feinberg School of Medicine who served as a principal investigator on OASIS 1, called the results "clinically meaningful." He noted that the oral route could remove a significant barrier for patients who are reluctant to use injections.
"There is a subset of patients who simply will not consider an injectable medication," Dr. Kushner said during a press briefing. "Now we can offer them an oral option that delivers comparable weight loss."
How the New Doses Work
Oral semaglutide uses Novo Nordisk's proprietary SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) absorption enhancer, which protects the peptide from stomach acid and helps it cross the gastric lining. Patients take the tablet on an empty stomach with no more than 4 ounces of plain water, then wait at least 30 minutes before eating, drinking, or taking other medications.
The dosing schedule starts at 3 mg daily for the first month, then increases to 7 mg, 14 mg, 25 mg, and finally 50 mg over a period of about 20 weeks. This gradual escalation reduces gastrointestinal side effects, which remain the most common reason patients discontinue GLP-1 therapy.
Side Effect Profile
The safety data from OASIS 1 was consistent with what clinicians already know about the GLP-1 drug class. The most frequently reported adverse events were gastrointestinal: nausea (affecting 33% of participants on the 50 mg dose versus 9% on placebo), diarrhea (17% versus 9%), and vomiting (12% versus 3%) [1].
Most GI side effects were mild to moderate and occurred during the dose-escalation period. Roughly 7% of participants on the 50 mg dose discontinued treatment due to adverse events, compared to 3% on placebo.
Dr. Ania Jastreboff, director of the Yale Obesity Research Center, pointed out that the side effect profile mirrors injectable semaglutide closely. "Patients and providers should expect the same types of GI effects," she said. "The oral route doesn't eliminate them, but it doesn't make them worse either."
What This Means for Patients
The approval opens a new option for the estimated 100 million American adults living with obesity [3]. For patients who have avoided GLP-1 therapy because of needle aversion, the oral formulation could be a practical alternative.
However, there are trade-offs to consider. The dosing requirements are strict. Taking the pill with food, coffee, or other medications sharply reduces absorption. Patients who struggle with the fasting requirement may find the injectable options more convenient despite the needles.
Insurance coverage remains an open question. Rybelsus has existing coverage for diabetes but weight management indications often face different formulary decisions. Novo Nordisk has not yet announced the list price for the higher-dose tablets, though analysts at Morgan Stanley estimated it will likely be priced in line with Wegovy's current list price of approximately $1,349 per month [4].
Prescription and Availability Timeline
Novo Nordisk expects the 25 mg and 50 mg tablets to reach pharmacies within six to eight weeks of the approval date. The company has stated it will prioritize the weight management indication to avoid the supply shortages that plagued Wegovy's early launch.
Patients currently taking Rybelsus 14 mg for diabetes can discuss the higher doses with their prescribers, though the weight management indication requires a separate prescription and potentially different insurance authorization.
The Bigger Picture for Oral GLP-1 Drugs
This approval is part of a broader shift in the GLP-1 market toward non-injectable delivery. Eli Lilly has an oral version of tirzepatide (the active ingredient in Mounjaro and Zepbound) in Phase 3 trials, with results expected in late 2026. Pfizer's oral GLP-1 candidate, danuglipron, reported mixed Phase 2 results but the company is continuing development [5].
For now, higher-dose Rybelsus stands alone as the only FDA-approved oral GLP-1 for weight management. That first-mover advantage could be significant in a market where patient preference increasingly drives prescribing decisions.
Sources
- Knop FK, et al. "Oral semaglutide 50 mg taken once daily in adults with overweight or obesity (OASIS 1)." The Lancet. 2023.
- Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity (STEP 1)." NEJM. 2021.
- CDC National Health and Nutrition Examination Survey, Obesity Prevalence Data. 2024.
- Morgan Stanley Research. "GLP-1 Market Update: Oral Semaglutide Pricing Analysis." February 2026.
- Pfizer Pipeline Update, Q4 2025 Earnings Call. January 2026.